Dissolution 711
Medium:
water; 500 mL.
Apparatus 1:
100 rpm.
Times:
30 minutes; 60 minutes.
Mobile phase and Chromatographic system
Prepare as directed in the Assay.
Procedure
Inject an accurately measured volume (about 50 µL) of a filtered portion of the solution under test into the chromatograph, record the chromatogram, and measure the response for the major peak. Calculate the quantity of C
15H
10Cl
2N
2O
2 dissolved by comparison of the peak response obtained from a similarly chromatographed Standard solution having a known concentration of
USP Lorazepam RS in water.
[NOTEA volume of alcohol not exceeding 10% of the final volume of the Standard solution is used initially to dissolve
USP Lorazepam RS.
]
Tolerances
The percentage of the labeled amount of C15H10Cl2N2O2 dissolved from the Tablets is not less than 60% (Q) in 30 minutes and not less than 80% (Q) in 60 minutes.
Uniformity of dosage units 905:
meet the requirements.
PROCEDURE FOR CONTENT UNIFORMITY
Diluent, Mobile phase, and Chromatographic system
Prepare as directed in the Assay.
Standard solution
Prepare as directed for Standard preparation in the Assay.
Test solution
Place 1 Tablet in a volumetric flask of appropriate size, based on the labeled quantity, in mg, of lorazepam in the Tablet, to obtain a solution having a concentration of about 0.1 mg of lorazepam per mL. Add a volume of Diluent equal to about 50% of the volume of the flask, sonicate for 10 minutes, and shake by mechanical means for 20 minutes. Dilute with Diluent to volume, mix, and centrifuge a portion of the solution for 10 minutes at 2000 rpm.
Procedure
Separately inject equal volumes (about 20 µL) of the
Test solution and the
Standard solution into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of lorazepam (C
15H
10Cl
2N
2O
2) in the Tablet taken by the formula:
(TC/D)(rU / rS),
in which
T is the labeled quantity, in mg, of lorazepam in the Tablet;
C is the concentration, in mg per mL, of
USP Lorazepam RS in the
Standard solution; D is the concentration, in mg per mL, of lorazepam in the
Test solution, based on the labeled quantity per Tablet and the extent of dilution; and
rU and
rS are the lorazepam peak responses obtained from the
Test solution and the
Standard solution, respectively.
Related compounds
A: Standard preparations
Prepare a solution in chloroform having known concentrations of 1.0 mg each of
USP Lorazepam Related Compound C RS,
USP Lorazepam Related Compound D RS, and
USP Lorazepam Related Compound E RS per mL. Dilute quantitatively with chloroform to obtain
Standard preparations, designated below by letter, having the following compositions:
Standard preparation |
Dilution |
Concentration (µg of each RS per mL) |
Percentage (%, for comparison with test specimen) |
A |
(1 in 25) |
40 |
2.0 |
B |
(1 in 50) |
20 |
1.0 |
C |
(1 in 100) |
10 |
0.5 |
Test preparation
Transfer a quantity of finely powdered Tablets, equivalent to 4.0 mg of lorazepam, to a sintered-glass funnel. Extract with two 1-mL portions of chloroform followed by two 1-mL portions of methanol, collecting the filtrate in a centrifuge tube. Evaporate the filtrate with the aid of a stream of nitrogen at room temperature to dryness. Dissolve the residue in 2.0 mL of chloroform, and centrifuge. Use the clear supernatant as the Test preparation.
Procedure
Within 30 minutes after preparation, apply separately 50 µL of the
Test preparation and 50 µL of each
Standard preparation to a suitable thin-layer chromatographic plate (see
Chromatography 621) coated with a 0.25-mm layer of chromatographic silica gel mixture and previously washed with a mixture of chloroform, ethyl acetate, and methanol (2:1:1) and dried in air. Allow the spots to dry, and develop the chromatograms in a solvent system consisting of a mixture of chloroform, dioxane, and glacial acetic acid (91:5:4) until the solvent front has moved to within 2 cm to 3 cm from the top of the plate. Remove the plate from the developing chamber, mark the solvent front, and allow to air-dry for about 30 minutes. Examine the plate under short-wavelength UV light. Compare the intensities of any secondary spots observed in the chromatogram of the
Test preparation with those of the principal spots in the chromatograms of the
Standard preparations: [NOTEThe
RF value and the intensity of the spot for the
USP Lorazepam Related Compound E RS in the
Standard preparations correspond closely, but not necessarily precisely, to those observed for one of the secondary spots observed in the chromatogram of the
Test preparation.
] The sum of the intensities of all secondary spots obtained from the
Test preparation corresponds to not more than 4.0%.
B:
Transfer a quantity of finely powdered Tablets, equivalent to 25.0 mg of lorazepam, to a tapered 15-mL centrifuge tube, add 2.5 mL of acetone, insert a stopper into the tube, mix by mechanical means, and centrifuge. Use the supernatant as the
Test preparation. Dissolve
USP Lorazepam Related Compound B RS in acetone to obtain a
Standard preparation having a known concentration of 100 µg per mL. Apply separately 50 µL of the
Test preparation and 5 µL of the
Standard preparation to a suitable thin-layer chromatographic plate (see
Chromatography 621) coated with a 0.25-mm layer of chromatographic silica gel mixture and previously washed with a mixture of chloroform, ethyl acetate, and methanol (2:1:1) and dried in air. Proceed as directed in test
B for
Related compounds under
Lorazepam, beginning with Allow the spots to dry. The spot produced by the
Test preparation is not greater in size or intensity than the principal spot produced at the corresponding
RF value by the
Standard preparation, corresponding to not more than 0.1% of 2-amino-2
¢,5-dichlorobenzophenone (lorazepam related compound B).
Assay
Diluent
Prepare a mixture of methanol and water (17:3).
Mobile phase
Prepare a filtered and degassed mixture of water, acetonitrile, and glacial acetic acid (60:40:0.4). Make adjustments if necessary (see
System Suitability under
Chromatography 621).
Standard preparation
Dissolve an accurately weighed quantity of
USP Lorazepam RS in
Diluent, and dilute quantitatively, and stepwise if necessary, with
Diluent to obtain a solution having a known concentration of about 0.10 mg per mL.
Assay preparation
Transfer 20 Tablets to a 100-mL volumetric flask. Add about 50 mL of Diluent, sonicate for 10 minutes, and shake by mechanical means for 20 minutes. Dilute with Diluent to volume, mix, and centrifuge a portion of the solution for 10 minutes at 2000 rpm. Quantitatively dilute an accurately measured volume of the clear supernatant with Diluent to obtain a solution containing about 0.1 mg of lorazepam per mL.
Chromatographic system (see Chromatography 621)
The liquid chromatograph is equipped with a 230-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1. The flow rate is about 1 mL per minute. Chromatograph the
Standard preparation, and record the peak responses as directed for
Procedure: the tailing factor is not more than 2.0; and the relative standard deviation is not more than 2.0%.
Procedure
Separately inject equal volumes (about 20 µL) of the
Standard preparation and the
Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of lorazepam (C
15H
10Cl
2N
2O
2) in each Tablet taken by the formula:
100(C / 20)(VU / V)(rU / rS),
in which
C is the concentration, in mg per mL, of
USP Lorazepam RS in the
Standard preparation; VU is the final volume, in mL, of the
Assay preparation; V is the volume, in mL, of the clear supernatant taken to prepare the
Assay preparation; and
rU and
rS are the peak responses obtained from the
Assay preparation and the
Standard preparation, respectively.